Sonoma Pharmaceuticals 

$2.09
0
-$0.1-4.57% Monday 04:00

Statistics

Day High
2.15
Day Low
2.05
52W High
-
52W Low
-
Volume
92
Avg. Volume
-
Mkt Cap
3.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15JulExpected
Q3 2025
Q4 2025
Next
-0.35
-0.28
-0.2
-0.13
Expected EPS
-0.24
Actual EPS
N/A

Financials

-24.2%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
28.58MRevenue
-6.91MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SNOA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson offers a wide range of healthcare products that compete with Sonoma Pharmaceuticals' dermatological and wound care products.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and markets drugs and vaccines, including those for infections and inflammations, competing with Sonoma's infection prevention products.
Merck
MRK
Mkt Cap214.76B
Merck produces pharmaceuticals that directly compete with Sonoma Pharmaceuticals in the areas of infection and wound care.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a strong portfolio in dermatology, directly competing with Sonoma Pharmaceuticals' skin health products.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a diverse range of healthcare products, including those for skin health and infection control, making it a competitor.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers various healthcare products that compete in the therapeutic areas covered by Sonoma Pharmaceuticals.
Novartis
NVS
Mkt Cap237.61B
Novartis provides innovative healthcare solutions, including dermatology and wound care products, competing with Sonoma Pharmaceuticals.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for skin conditions and infections, competing with Sonoma's product range.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals specializes in biopharmaceuticals, competing in the dermatology and infection prevention market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries offers generic and specialty medicines, including dermatological products, competing with Sonoma Pharmaceuticals.

About

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Show more...
CEO
ISIN
US83558L3033

Listings

0 Comments

Share your thoughts

FAQ

What is Sonoma Pharmaceuticals stock price today?
The current price of SNOA.BOATS is $2.09 USD — it has decreased by -4.57% in the past 24 hours. Watch Sonoma Pharmaceuticals stock price performance more closely on the chart.
What is Sonoma Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sonoma Pharmaceuticals stocks are traded under the ticker SNOA.BOATS.
What is Sonoma Pharmaceuticals market cap?
Today Sonoma Pharmaceuticals has the market capitalization of 3.62M
When is the next Sonoma Pharmaceuticals earnings date?
Sonoma Pharmaceuticals is going to release the next earnings report on July 15, 2026.
What were Sonoma Pharmaceuticals earnings last quarter?
SNOA.BOATS earnings for the last quarter are -0.35 USD per share, whereas the estimation was -0.29 USD resulting in a -21.23% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sonoma Pharmaceuticals revenue for the last year?
Sonoma Pharmaceuticals revenue for the last year amounts to 28.58M USD.
What is Sonoma Pharmaceuticals net income for the last year?
SNOA.BOATS net income for the last year is -6.91M USD.
When did Sonoma Pharmaceuticals complete a stock split?
Sonoma Pharmaceuticals has not had any recent stock splits.